Takeda granted generics firm Teva a license to market authorized copies in the US, starting Aug. 17, 2012, for best-selling diabetes pill Actos, and on Dec. 14, 2012, for Actoplus met (Actos plus metformin). Under the agreement, Teva can sell generic versions of Actos during the 180-day exclusivity period otherwise reserved for first-filers Mylan, Watson and Ranbaxy. Takeda said it previously settled with those three generics firms for an entry date of 8/17/12 for Actos, with Mylan for a 12/14/12 entry for generic Actoplus met, and with Sandoz for a 12/14/12 entry for generic duetact (Actos plus glimepiride). Takeda settled with multiple second filers for entry dates six months after the first filers. Patents relating to all three products expire in 2016, Takeda said, and the company had filed lawsuits against the generics makers to enforce them. Actos had 2009 US wholesale acquisition cost sales of $3.2 billion, Actoplus met $439 million, according to data from Wolters Kluwer Pharma Solutions.
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.